Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead Drug Candidate, Bryostatin-1, for the Treatment of Advanced Alzheimer’s …

is lower in apoE4 transgenic mice compared with apoE3 mice, indicating impaired synaptogen-esis (12, 13). ApoE4 is less efficient than apoE3 in transporting brain cholesterol (14) and is also less e fective …

NEW YORK, March 16, 2017 PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, …

The complete publication in the Trends in Pharmacological Sciences: CellPress Reviews can be accessed here: https://www.synaptogen.com/wp-content/uploads/2019//08/TiPS2019.pdf and is also …

Bryostatin, currently being tested in a Phase 2b clinical trial in Alzheimer’s Dementia, causes regeneration of synaptic networks in both Alzheimer’s and Fragile X mouse models, …

Plantation, FL. – June 19, 2014 – Neurotrope, Inc. (OTCQB: NTRP) has appointed Messrs. Charles S. Ramat and Paul Freiman as Co-Chairmen of its Board of Directors. Mr. Freiman previously served …

NEW YORK, May 28, 2020 – Neurotrope, Inc. (Nasdaq: NTRP) today announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer’s disease (AD). The …

Plantation, FL. – October 7, 2013 – Neurotrope, Inc. (formerly BlueFlash Communications, Inc.) (OTCQB:NTRP), a Nevada corporation (the “Company”), announced today that it has formally hired …

Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute

Morgantown, WV 26505 Running title: Rescuing synapses and spatial memory in young fragile X mice